Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2010 - 2026)

Lineage Cell Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $45.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 5.45% year-over-year to $45.3 million; the trailing twelve-month figure through Mar 2026 stood at $45.3 million (down 5.45% YoY), and the FY2025 full-year result was $46.0 million, up 12.06% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $45.3 million, down from $46.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $78.1 million in Q1 2022, with the low at $11.4 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $38.3 million across 5 years, with a median of $35.4 million in 2023.
• The largest YoY upside for Cash & Equivalents was 212.13% in 2023 against a maximum downside of 80.21% in 2023.
• Lineage Cell Therapeutics' Cash & Equivalents stood at $11.4 million in 2022, then soared by 212.13% to $35.4 million in 2023, then climbed by 15.73% to $41.0 million in 2024, then climbed by 12.06% to $46.0 million in 2025, then declined by 1.5% to $45.3 million in 2026.
• The last three Cash & Equivalents figures came in at $45.3 million (Q1 2026), $46.0 million (Q4 2025), and $32.2 million (Q3 2025), per Business Quant data.